Cosmo N.V.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Giovanni di Napoli
- Full Time Employees
- 325
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Riverside 2 Dublin DU Ireland D02 KV60
- IPO Date
- May 18, 2016
- Website
- cosmopharma.com
- Similar Companies
- Business
- Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company focused on the development, manufacture, and commercialization of innovative therapies for gastrointestinal and central nervous system disorders. The company operates as a vertically integrated drug developer and provider, advancing products from discovery through clinical development to commercial launch. Primary business activities include Research and Development of proprietary small molecule and biotechnological therapies; GMP manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms; scale-up, formulation, and process development; regulatory affairs, quality assurance, and pharmacovigilance; and strategic partnerships, licensing, and collaborations to maximize product commercialization. Main products and services - Proprietary therapies for inflammatory and functional gastrointestinal diseases; small molecule drug candidates addressing motility and secretory pathways; CNS-targeted programs exploring neuropsychiatric indications - API development and manufacturing; formulation development; clinical trial material production; commercial-scale manufacturing of finished dosage forms - Research services and early-stage development collaboration capabilities; preclinical study design and tox assessments; pharmacokinetic and pharmacodynamic profiling - Regulatory affairs and quality management; GMP-compliant manufacturing facilities; quality assurance, stability testing, and supply chain oversight - Licensing, co-development, and strategic partnerships; in-licensing of external assets; co-development agreements; product in-licensing and out-licensing activities Latest major company changes - Entered strategic partnerships and licensing agreements to advance late-stage and early-stage programs with pharmaceutical partners - Announces acquisitions or divestitures affecting portfolio composition and operational focus - Launches or expands product lines or service offerings through internal development milestones or external collaborations - Undergoes organizational restructurings or name changes aligning with broader corporate strategy - Implements significant operational changes in the past 1–2 years, including facility expansions, capacity enhancements, or manufacturing network optimization Additional context - Industry: Pharmaceuticals and biopharmaceuticals; focuses on gastrointestinal and CNS therapeutic areas - Business segments: Drug discovery and development; contract development and manufacturing; clinical and regulatory services - Target markets: Global pharmaceutical companies, healthcare providers, and patients seeking innovative therapies - Geographic operations: Global operations with development and manufacturing activities; headquarters in Europe; presence in multiple regions through subsidiaries, collaborations, and licensing arrangements - Founding year and headquarters: Cosmo Pharmaceuticals N.V. founded in the early 2000s; headquartered in the Netherlands - Subsidiaries/parent relationships: Operates subsidiaries and affiliates enabling regional development, manufacturing, and commercialization; engages with parent or umbrella corporate structures for strategic oversight
Company News
Cosmo N.V. (CMOPF) Discusses Positive Phase 2 Results and Differentiation of Rifamycin 1% Gel in Ulcerative Colitis and Proctitis Transcript
Cosmo Announces Positive Phase 2 Study of Rifamycin 1% Topically Acting Gel, Meeting the Primary Endpoint in Distal Ulcerative Colitis and Ulcerative Proctitis
Largest Real-World Study of the GI Genius(TM) Intelligent Endoscopy System Demonstrates Improved Adenoma Detection in Routine Clinical Practice
Cosmo Announces SIX Ticker Symbol Change to "CMHC"
Cosmo N.V. (CMOPF) Q2 2026 Earnings Call Transcript
Cosmo Reports Double-Digit Recurring Revenue Growth in H1 2026, Advances Clascoterone 5% Topical Solution Toward Regulatory Submission, and Confirms Full-Year Guidance
Invitation to Cosmo's Half-Year 2026 Financial Results Webcast on 23 July 2026
Cosmo Welcomes the Launch of Winlevi(R) in Key European Markets by Its Partner Glenmark
Cosmo Announces Completion of Phase II Enrolment in Distal Ulcerative Colitis Program
Phase III 12-Month Data for Clascoterone 5% Topical Solution Confirm Positive Safety for Chronic Use and Continued Hair Growth, both of which are Statistically Significant
Voting Results of Cosmo's 2026 AGM
Cosmo Pharmaceuticals N.V. (CMOPF) Q4 2025 Earnings Call Transcript
Cosmo Pharmaceuticals Achieves 104.2M Revenue and 9.5M EBITDA in 2025; Proposes 2.10 Dividend; Establishes 2026 Growth Framework
Cosmo Announces Strategic R&D Collaboration to Advance AI-Based Detection of Early Neoplasia in Barrett's Esophagus
Cosmo Pharmaceuticals Announces Private Placement of Treasury Shares
Invitation to Cosmo's Full Year 2025 Financial Results Webcast on 9 March 2026
Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms
Cosmo Pharmaceuticals (OTC:CMOPF) Stock Price Up 1.1% – Here’s What Happened
The Hair-Loss Cure That Just Sent This Stock Exploding 24%--Is Big Pharma Paying Attention?
Cosmo Announces Breakthrough Phase III Topline Results from Scalp 1 and Scalp 2 for Clascoterone 5% Solution in Male Hair Loss, Showing up to 539% Relative Improvement in Target-Area Hair Count vs Placebo; US and EU Submissions are Underway